### C014CIP/DIV1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Phillip Gambel

Group Art Unit

1644

Applicants : Michael J. Yellin et al.

Serial No. : 09/343,001 Confirmation No.: 7400

Filed

: July 29, 1999

For

THERAPEUTIC APPLICATIONS FOR THE ANTI-T-BAM (CD40-L) MONOCLONAL ANTIBODY 5C8 IN THE TREATMENT OF CHRONIC INFLAMMATORY

DISEASE

New York, New York June 13, 2001

Hon. Commissioner for Patents Washington, D.C. 20231

# SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants make of record the following documents, copies of which are submitted herewith:

#### United States Patents

5,961,974 (Armitage et al.) issued October 5, 1999

03/E1/E001 RZERBRU1 00000069 09343001

08 TC:125

180.00 SP

### Other Documents

Press Release from IDEC Pharmaceuticals, Inc. (January 29, 2001).

Kalled, S.L. et al. "Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis", Lupus, 10: 9-22 (2001).

For the Examiner's convenience, the above-mentioned documents are listed on the accompanying Form PTO-1449.

Applicants respectfully request that the above-cited documents be (1) fully considered by the Examiner during the continued examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO-1449, duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

Since this Second Supplemental Information

Disclosure Statement is submitted more than three months from

the application filing date and after the mailing date of the

first Office Action, but before the mailing date of either a

final action under 37 C.F.R. § 1.113, or a Notice of Allowance

under 37 C.F.R. § 1.311, a check in payment of the \$180.00

fee, pursuant to 37 C.F.R. § 1.17(p), is transmitted herewith.

Additionally, the transmittal letter accompanying this

document, sent in duplicate, states that the Director is

hereby authorized to charge payment of any additional fees

required in connection with this Second Supplemental
Information Disclosure Statement to Deposit Account No. 061075.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27, 794)

Margaret A. Pierri (Reg. No. 30,709)

Attorneys for Applicants

Shawn-Marie Mayrand (Reg. No. P-48,986)

Agent for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas New York, New York 10020-1104

Tel.: (212) 596-9000 Fax: (212) 596-9090

I Beroby Certify that this Correspondence is being Deposited with the U.S. Portal Service as First Class Mail in an Enclope Addrespond to: MESISTARY COMMITTEIONER FOR PRIMERED.

MACHINGTON, D.C. 20231 on

gnoture or leaves signing